News for Intensity Therapeutics Inc Stock (INTS)

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

PRNewsWire • 12/12/24

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

PRNewsWire • 11/21/24

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

PRNewsWire • 11/18/24

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PRNewsWire • 11/13/24

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

PRNewsWire • 11/08/24

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

PRNewsWire • 10/31/24

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

PRNewsWire • 09/04/24

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

PRNewsWire • 08/08/24

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

PRNewsWire • 07/09/24

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

PRNewsWire • 05/15/24

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

Seeking Alpha • 05/14/24

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

PRNewsWire • 05/10/24

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

PRNewsWire • 05/09/24

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

PRNewsWire • 04/02/24

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

PRNewsWire • 03/14/24

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

PRNewsWire • 03/14/24

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

PRNewsWire • 02/21/24

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

PRNewsWire • 01/03/24

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

PRNewsWire • 12/12/23

Why Is Intensity Therapeutics (INTS) Stock Up 133% Today?

InvestorPlace • 12/08/23

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

PRNewsWire • 12/08/23

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

PRNewsWire • 12/01/23

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

PRNewsWire • 11/13/23

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

PRNewsWire • 11/02/23

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

PRNewsWire • 09/07/23